These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35341215)

  • 1. Corrigendum: Impact of Non-Persistence on Healthcare Resource Utilization Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study.
    Carballo N; Garcia-Alzórriz E; Ferrández O; Navarrete-Rouco ME; Durán-Jordà X; Pérez-García C; Monfort J; Cots F; Grau S
    Front Pharmacol; 2022; 13():867017. PubMed ID: 35341215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
    Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
    Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.
    Dalén J; Svedbom A; Black CM; Kachroo S
    Rheumatol Int; 2017 Dec; 37(12):2049-2058. PubMed ID: 28975392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of persistence with tumour necrosis factor inhibitors on healthcare resource utilization and costs in chronic inflammatory joint diseases.
    Belhassen M; Tubach F; Hudry C; Woronoff-Lemsi M; Levy-Bachelot L; Van Ganse E; Fautrel B
    Br J Clin Pharmacol; 2021 Jan; 87(1):163-177. PubMed ID: 32441383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line.
    Svedbom A; Dalén J; Black CM; Kachroo S
    Patient Prefer Adherence; 2017; 11():95-106. PubMed ID: 28144130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
    Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
    J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of non-persistence on the direct and indirect costs in patients treated with subcutaneous tumour necrosis factor-alpha inhibitors in Germany.
    Ziegelbauer K; Kostev K; Hübinger M; Dombrowski S; Friedrichs M; Friedel H; Kachroo S
    Rheumatology (Oxford); 2018 Jul; 57(7):1276-1281. PubMed ID: 29660105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
    Chen KC; Wu CH; Tang CH; Huang KC
    PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum: TNF-α in Uveitis: From Bench to Clinic.
    Jiang Q; Li Z; Tao T; Duan R; Wang X; Su W
    Front Pharmacol; 2022; 13():817235. PubMed ID: 35281920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics.
    Nadkarni A; McMorrow D; Fowler R; Smith D
    J Comp Eff Res; 2017 Nov; 6(8):659-669. PubMed ID: 28791873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors.
    Tymms K; Littlejohn G; Griffiths H; de Jager J; Bird P; Joshua F; Nash P; Handel M; McManus H; Butcher BE; Youssef P
    Clin Rheumatol; 2018 Jun; 37(6):1617-1623. PubMed ID: 29667098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study.
    Dalén J; Luttropp K; Svedbom A; Black CM; Kachroo S
    Adv Ther; 2020 Sep; 37(9):3746-3760. PubMed ID: 32647910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
    Vanderpoel J; Tkacz J; Brady BL; Ellis L
    Clin Ther; 2019 Jun; 41(6):1080-1089.e5. PubMed ID: 31122662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis.
    Baser O; Ganguli A; Roy S; Xie L; Cifaldi M
    Clin Ther; 2015 Jul; 37(7):1454-65. PubMed ID: 25999184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
    Armstrong AW; Foster SA; Comer BS; Lin CY; Malatestinic W; Burge R; Goldblum O
    BMC Dermatol; 2018 Jun; 18(1):4. PubMed ID: 29954363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan.
    Chen DY; Yu F; Tuan LW; Tang CH
    Front Pharmacol; 2019; 10():1214. PubMed ID: 31695611
    [No Abstract]   [Full Text] [Related]  

  • 18. Healthcare resource utilization and costs in patients with HIV-1 who switched first-line antiretroviral therapy.
    Mao J; Johnson MP; McPheeters JT; Prajapati G; Beyer AP
    Curr Med Res Opin; 2019 Nov; 35(11):1945-1953. PubMed ID: 31311342
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
    Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
    J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with rheumatic diseases share similar patterns of healthcare resource utilization.
    Mars NJ; Kerola AM; Kauppi MJ; Pirinen M; Elonheimo O; Sokka-Isler T
    Scand J Rheumatol; 2019 Jul; 48(4):300-307. PubMed ID: 30836033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.